Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -63.97 | -24.65 | -20.69 |
| EBIT | -- | -- | 32.88 | 9.51 | -11.37 |
| Net Profit | 51.09 | 51.06 | -104,493.52 | 3.92 | -51.94 |
| EPS | 51.22 | 51.51 | -13,950.25 | 9.53 | 10.43 |
| Book Value | -- | -- | -59.37 | -33.79 | -24.73 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-23 | Dec-22 | Dec-21 |
| EBIT-Margin
| -4,134.80 | -4,764.92 | -7,967.30 | -4,154.64 | -282.44 |
| Net Margin
| -139.74 | -1,132.10 | -- | 0.35 | -279.83 |
| Return on equity
| -47.34 | -48.23 | -90.02 | 0.28 | -52.28 |
| Return on Capital
| -42.38 | -44.89 | -80.18 | 0.24 | -47.20 |
| Return on Assets
| -27.42 | -32.18 | -42.26 | 0.22 | -40.21 |
| Debt to Equity (x)
| -- | -- | 0.02 | 0.17 | 0.14 |
Profitability
ROCE
-80.18
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-80.18
|
0.24
|
-47.20
|
-54.10
|
-43.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-90.02
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-90.02
|
0.28
|
-52.28
|
-55.94
|
-43.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-42.26
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-42.26
|
0.22
|
-40.21
|
-44.27
|
-34.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-7,967.30
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-7,967.30
|
-4,154.64
|
-282.44
|
-4,820.98
|
-6,599.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-9,771.71
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-9,771.71
|
0.35
|
-279.83
|
-2,976.47
|
-1,272.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.64
--
Year on year growth in net sales
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-0.64
|
-0.91
|
11.57
|
0.62
|
-0.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
30.90
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
30.90
|
-38.91
|
26.34
|
-18.48
|
-78.58
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-23,487.37
--
Year on year growth in profit after tax
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-23,487.37
|
100.51
|
24.81
|
-29.87
|
-71.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-232.73
--
Year on year growth in earnings per share
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-232.73
|
1.01
|
0.40
|
-0.30
|
-0.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.02
--
Total debt / Net worth
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.02
|
0.17
|
0.14
|
0.08
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.02
|
0.01
|
0.00
|
0.01
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.25
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
7.25
|
8.02
|
11.14
|
9.69
|
21.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
--
|
--
|
--
|
9.69
|
21.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
--
|
-0.51
|
-518.64
|
-83.02
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
--
|
9.35
|
--
|
14.80
|
24.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
--
Sales / Average Total Assets
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.00
|
0.01
|
0.14
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
94.79
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
94.79
|
34.16
|
4.30
|
54.07
|
131.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
--
|
--
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
1,383.27
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
1,383.27
|
246.64
|
135.63
|
13.33
|
37.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
--
|
--
|
-131.33
|
40.74
|
94.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.31
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
-0.31
|
149.96
|
-2.17
|
-4.02
|
-9.55
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.48
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.48
|
0.41
|
1.23
|
2.61
|
3.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.50
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Homology Medicines (FIXX)
|
0.50
|
0.28
|
-0.87
|
-2.52
|
-6.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|